Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Progesterone for Luteal Phase Deficiency
NCT02950948Phase 3Withdrawn
- Sponsor
- IBSA Group
- Start
- May 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in Luteal phase deficiency (LPD) comparing Progesterone with Placebo (2 arms). Primary endpoint: Ongoing pregnancy rate at 12 weeks of gestation. Planned start May 2017; status: withdrawn.
02
Drugs
progesterone
03
Conditions
Luteal phase deficiency (LPD)
Beyond the preview
Go deeper on NCT02950948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950948.